Medetomidine, is a potent, selective and specific alpha-2 adrenoceptor agonist. Alpha-2 adrenoceptor activation by medetomidine induces a dose-dependent decrease in the release and turnover of noradrenaline in the central nervous system, which is manifested as sedation, analgesia and bradycardia. In the periphery, medetomidine causes vasoconstriction by activating postsynaptic alpha-2 adrenoceptors in the vascular smooth muscle. Thus the blood pressure initially increases after medetomidine injection due to an increase in systemic vascular resistance. The pressure reverts to normal or slightly below within 1 to 2 hours. The respiratory frequency may transiently be lowered.
The duration and degree of the sedative and analgesic effects depend on the dose administered. During maximal effect the animal is relaxed, lies down and does not react to external stimuli. Marked synergistic effects have been demonstrated between medetomidine and cyclohexamine compounds such as ketamine, and between medetomidine and opiate drugs such as fentanyl, producing deep anaesthesia. Similarly medetomidine has a very potent ability to reduce dose requirements of intravenous and inhalation anaesthetics.
Medetomidine is rapidly absorbed after intramuscular injection. Peak concentration is reached within 15-20 minutes. It is readily metabolised and excreted in the urine and in the faeces (half lives of elimination ranging from 1 to 1.6 hours).
Store below 30°C (room temperature). Protect from light. Store vials upright. Do not freeze. Once broached, the product must be used within 3 months.
It is presented in clear solution 10 mL glass vial